Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0079731 (B-cell lymphoma)
 16,671 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Apoptosis or programmed cell death is observed in a variety of organisms and tissues and is characterized by distinct morphologic changes to the cell. Although early indicators of this process have been described, their functional relevance remains unknown. We have used two-dimensional gel electrophoresis to look for characteristic and consistent changes in the phosphorylation state of proteins during apoptosis, induced by different agents, in the B cell lymphoma line, BM13674, and the T cell leukemia line, CEM-C7. We report that apoptosis induced by either heat treatment or by ionizing radiation exposure is accompanied by dephosphorylation of a limited number of specific proteins. The pattern of dephosphorylation was similar after both treatments in BM13674 cells. In CEM-C7 cells, dephosphorylation was also observed after heat and irradiation. One of these proteins corresponded to one dephosphorylated in BM13674 cells. Okadaic acid, an inhibitor of phosphatases 1, 2A, and, to a lesser extent, 2B, prevented apoptosis in all cases and inhibited dephosphorylation of this common protein as well as some of the others. It seems likely that activation of a phosphatase(s) or loss of activity of a kinase is of central importance in apoptosis in these systems.
 ...
PMID:Specific protein dephosphorylation in apoptosis induced by ionizing radiation and heat shock in human lymphoid tumor lines. 154 32

We have studied the potential use of immunotoxins (ITs) for therapeutic treatment of human tumors in an experimental model of human neoplasia. We tested intact ricin IT for its antitumor activity against established tumors. CEM, a human T-cell leukemia line expressing an Mr 67,000 cell surface antigen, and Daudi, a human B-cell lymphoma line which does not express the antigen, were found to be consistently tumorigenic in nude mice. ITs were synthesized using T101, a high-affinity monoclonal antibody reacting with the Mr 67,000 protein determinant and intact ricin. We have shown for the first time that established CEM solid tumors in nude mice will regress following intratumoral injection of T101-ricin IT, while Daudi tumors will not. Selective activity of T101-ricin is dependent on systemic i.v. administration of lactose and local intratumoral injection of the T101-ricin IT with lactose. Intact ricin ITs require the presence of lactose to block native ricin binding and render them antigen specific when linked to monoclonal antibody. Killing of target was cell specific since (a) nonspecific (irrelevant) ITs did not cause the regression of CEM tumors, and (b) injection of large amounts of free T101 antibody prior to T101-ricin IT blocked antitumor activity. Selectivity was not absolute, since regression occurred in one of six animals given irrelevant IT, and blocking was observed in two of four mice. Intratumoral IT treatment with 1 or 2 micrograms of T101-ricin IT plus lactose was not harmful to mice in contrast to intratumoral ricin treatment, which killed all treated tumor-bearing mice at a dose of 0.3 micrograms. Without i.v. injection of lactose, intratumoral injection of T101-ricin IT was also effective in eliminating established tumors. However, this treatment did not result in the selective elimination of tumor, since Daudi tumors also regressed following T101-ricin IT treatment. IT, made with ricin A chain only (T101-A chain IT), was also tested against established CEM tumors. We found that high dosages of T101-A chain IT did not destroy CEM tumors when injected intratumorally, even in the presence of activating agents such as NH4Cl or the carboxylic ionophore X-537 A. In contrast, in vitro experiments demonstrated that T101-A chain IT plus activating agents had potent and selective cytotoxic effect against CEM cells. We conclude that ITs are specifically toxic to established tumors. Although selectivity is not absolute, ITs exhibit potential as a new class of antitumor reagents.
 ...
PMID:Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. 397 76

The human homologue of 4-1BB (H4-1BB) cDNA was isolated from PMA plus ionomycin-treated human peripheral T-cell cDNA libraries. The amino acid sequence deduced from the nucleotide sequence showed that the protein is composed of 255 amino acids with 2 potential N-linked glycosylation sites. The molecular weight of its protein backbone is calculated to be 27 kDa. The H4-1BB contains features such as signal sequence and transmembrane domain, indicating that it is a receptor protein. This protein showed 60% identity of amino acid sequence to mouse 4-1BB. In the cytoplasmic domain there are 5 regions of amino acid sequences conserved from mouse to human, indicating that these residues might be important in the 4-1BB function. H4-1BB mRNA was detected in unstimulated peripheral blood T cells and was inducible in T-cell lines such as Jurkat and CEM. H4-1BB-AP, a fusion protein between the H4-1BB extracellular domain and alkaline phosphatase, was used to identify the ligand for the H4-1BB. Although the H4-1BB ligand was detected in both T and B cells of human peripheral blood, the ligand was preferentially expressed in primary B cells and B-cell lines. Daudi, a B-cell lymphoma, was one of the B-cell lines that carried a higher number of ligands. Scatchard analysis showed that the Kd = 1.4 x 10(9) M and the number of ligands in Daudi cell was 4.2 x 10(3).
 ...
PMID:Characterization of human homologue of 4-1BB and its ligand. 762 90

We studied the effects of carboplatin in combination with etoposide in human B-cell lymphoma cell lines, BALL-2, Dauji and human T-cell leukemia cell lines, CEM, HSB and MOLT-3 cells. Cells were incubated for 3 days in the presence of carboplatin and etoposide, and the combined drug and cell growth inhibition was determined by MTT assay. The effects of drug combinations at ID80 were analyzed by an improved isobologram method (Steel and Peckham). In the combination of carboplatin with etoposide, the data points fell in the envelope of additivity (additive effect) in all five cell lines. Synergistic and antagonistic effects were not observed. These findings suggest that the combination of carboplatin and etoposide are as effective as expected.
 ...
PMID:[Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines]. 871 22

To study the expression of tankyrase (a positive regulator of telomerase activity) in malignant hematopoietic cells and its relation with telomerase activity, the method of realtime quantitative PCR with fluorescence probe hybridization were used to measure expression of tankyrase and hTERT in myeloid leukemia cell lines K562, HL-60, U937, NB4, THP-1, HEL, Dami and T lymphocytic leukemia cell lines 6T-CEM, Jurkat and B-cell lymphoma cell line Raji. CD3(+), CD19(+) and CD33(+) cells separated from normal human mobilized peripheral blood by immunomagnetic bead system and 10 mononuclear cell samples separated from bone marrow of normal individuals were served as normal controls. The results indicated that the expression of tankyrase in malignant hematopoietic cell lines was significantly higher than that in normal controls (U = 19, P < 0.01). Its expression in myeloid leukemia cell lines is higher than in normal CD33(+) cells, the expression in T lymphocytic leukemia and B-cell lymphoma cell lines is higher than in CD3(+) and CD19(+) cells respectively. Its expression in myeloid malignant hematopoietic cell lines is significantly lower than in lymphocytic ones (0.0032 +/- 0.0010 vs. 0.012 +/- 0.0016, F = 23, P < 0.01). The expression of tankyrase correlated positively with hTERT (Spearman correlation coefficient is 0.395, P < 0.05). It is concluded that tankyrase is overexpressed in malignant hematopoietic cell lines, that may be one of the causes of high-produced telomerase activity in malignant hematopoietic diseases.
 ...
PMID:[Study on the expression of tankyrase in malignant hematopoietic cells and its relation with telomerase activity]. 1498 61

The human cell lines CCRF-CEM (T-cell acute lymphocytic leukemia), HL-60 (acute myeloid leukemia), MEC-1 (B-cell chronic lymphocytic leukemia) and Raji (Burkitt's B-cell lymphoma) have been analysed for differences in their nuclear proteomes. Using 2-D DIGE, 55 nuclear proteins have been identified that are differentially expressed (p<0.025) between the four cell lines, including proteins associated with transcription, proliferation, DNA repair and apoptosis. Of these 55 proteins, 22 were over-expressed in just one cell line, and four were down-regulated in one cell line. Proteins uniquely over-expressed between myeloid and lymphoid cell lines include those that may have use as markers for diagnosis, disease progression and B-cell maturation and differentiation. Expression of various proliferation-associated nuclear proteins correlated with relative growth rates of the cell lines, giving these proteins potential diagnostic applications for distinction of chronic versus acute subtypes of haematological malignancies. Identification of these differentially expressed nuclear proteins should facilitate elucidation of the molecular mechanisms underlying leukocyte differentiation and transformation to leukemias and lymphomas. The nuclear expression profiles should enable classification of subtypes of leukemia, and identify potential nuclear protein targets for development of diagnostic and therapeutic strategies.
 ...
PMID:Differentially expressed nuclear proteins in human CCRF-CEM, HL-60, MEC-1 and Raji cells correlate with cellular properties. 2113 23